

# Multidisciplinary management of a patient with synchronous neoplasms: A case report of breast cancer plus pheochromocytoma

## Manejo multidisciplinario de paciente con neoplasias sincrónicas: reporte de un caso clínico de cáncer de mama y feocromocitoma

Sheila Huertas T<sup>1</sup> , José Vargas M<sup>1</sup> , Ciro Espejo A<sup>2</sup> 

<sup>1</sup> Cayetano Heredia National Hospital.

<sup>2</sup> Endocrinology Service, Department of Medicine.

**Received:** 10/10/2025

**Accepted:** 18/01/2026

**Published:** 01/04/2026

### ABSTRACT

**Introduction:** Synchronous neoplasms are a rare phenomenon. It is reported that patients with breast cancer and synchronous neoplasms most frequently develop malignant tumors in the thyroid gland (71%) or the gynecological tract (9.7%). There is no established association with pheochromocytoma, as the presence of both synchronous neoplasms is extremely rare. This case describes an atypical association of two neoplasms and their multidisciplinary approach in a public institution in Peru. **Case report:** Postmenopausal patient who presented with a breast tumor compatible with malignant neoplasm. Extension studies incidentally evidenced an adrenal mass with characteristics of malignancy, initially suspecting a focus of secondary metastasis. Complementary studies evidenced elevated serum and urinary metanephrines, leading to the diagnosis of pheochromocytoma. Initially, a right adrenalectomy was performed, followed later by a radical mastectomy, obtaining high-risk pathology (grade II with lymphovascular invasion, perineural invasion, and nodal macrometastases). **Discussion:** Synchronous neoplasms present a challenge in the diagnosis and treatment of the oncological patient. In this case, the surgical management of pheochromocytoma was prioritized due to the risk of cardiovascular complications. Delay in the management of breast pathology is a factor associated with the presence of high-risk scenarios, characterized by disease in more advanced stages, a greater probability of tumor progression, and worst oncological outcomes. **Conclusions:** The management of multiple neoplasms should be individualized according to the characteristics of each neoplasm and risk of complications. It is necessary to report cases of atypical associations of multiple neoplasms to broaden the diagnostic spectrum and improve the therapeutic approach for patients.

**Keywords:** Synchronous neoplasms, pheochromocytoma, breast cancer, clinical case.

### RESUMEN

**Introducción:** Las neoplasias sincrónicas son poco frecuentes. Se reporta que los pacientes con cáncer de mama y neoplasias sincrónicas desarrollan con mayor frecuencia tumores malignos en la glándula tiroidea (71 %) o en el tracto ginecológico (9,7 %); pero no existe ninguna asociación establecida con el feocromocitoma, ya que la presencia de ambas neoplasias sincrónicas es extremadamente rara. Este caso describe una asociación atípica de dos neoplasias y su abordaje multidisciplinario en una institución pública de Perú. **Caso clínico:** Paciente posmenopáusica consulta por tumoración en la mama compatible con una neoplasia maligna, en estudios de extensión se evidencia incidentalmente una masa suprarrenal con características de malignidad, con sospecha inicial de un foco metastásico. En estudios complementarios se evidencia elevación de metanefrinas séricas y en orina. El diagnóstico fue feocromocitoma. Inicialmente, se realizó una adrenalectomía derecha y luego la

\* **Corresponding Author:** Sheila Maria Huertas Tirado, [sheilaht92@gmail.com](mailto:sheilaht92@gmail.com)

**How to cite:** Huertas Tirado S, Vargas J & Espejo C. Multidisciplinary management of a patient with synchronous neoplasms: A case report of breast cancer plus pheochromocytoma. *Oncología (Ecuador)*. 2026;36(1): 1-7. <https://doi.org/10.33821/824>

mastectomía radical; el resultado histopatológico fue de alto riesgo (grado II con invasión linfovascular, perineural y macrometástasis ganglionar). **Discusión:** Las neoplasias sincrónicas representan un desafío al diagnóstico y tratamiento del paciente oncológico. En este caso se priorizó el manejo quirúrgico del feocromocitoma ante el riesgo de complicaciones cardiovasculares. La demora en el manejo de la patología mamaria es un factor asociado a presencia de escenarios de alto riesgo, caracterizados por enfermedad en estadios más avanzados, mayor probabilidad de progresión tumoral y peores resultados oncológicos. **Conclusiones:** El manejo de neoplasias múltiples debe ser individualizado según las características de cada neoplasia y riesgo de complicaciones. Es necesario reportar casos de asociaciones atípicas de neoplasias múltiples para ampliar el espectro diagnóstico y mejorar el abordaje terapéutico de los pacientes.

**Palabras clave:** neoplasias sincrónicas, feocromocitoma, cáncer de mama, caso clínico.

## 1. Introduction

Synchronous neoplasms are defined as two or more malignant tumors of different histopathological origins diagnosed within the first six months. This is considered a rare phenomenon; the presence of multiple primary neoplasms is estimated to range between 0.73% and 11.7%. [1,2]. LV et al. [3] described the incidence of synchronous neoplasms in 161 patients, demonstrating a high frequency of synchronism in gastric cancer (13%), lung cancer (12%), and esophageal cancer (11.8%). Some studies report the prevalence of synchronous neoplasms ranging from 15% to 34% in patients with breast cancer [4,5]. Other studies report a worse prognosis in this group of patients varies according to clinical stage, histological grade, and treatment [6–8]. Chen et al. [9] described a difference greater than 10% in overall survival among patients with colorectal cancer with synchronous tumors compared to patients with a single primary tumor (61.9% vs. 73.7%, respectively).

The development of multiple neoplasms is associated with extrinsic patient-related factors, such as harmful habits, occupational risks, level of physical activity, or a combination of both. It is also associated with intrinsic factors, including immune system alterations or genetic mutations in susceptibility genes, for instance, BRCA and PTEN. [2, 10–11] In breast cancer, the presence of synchronous neoplasms has been associated with radiotherapy and cytotoxic agents, which controversially constitute part of its treatment. [2, 10]. A study conducted in Korea reports that patients with breast cancer and synchronous neoplasms more frequently develop malignant tumors of the thyroid gland (71%) or the gynecologic tract (9.7%) [12]. Additionally, other studies have reported a higher rate of synchronism in luminal breast cancer and advanced-stage disease [13].

Herein, we present the case of a patient with two synchronous neoplasms—an atypical combination of breast cancer and pheochromocytoma—and its multidisciplinary therapeutic management.

## 2. Case Report

A 47-year-old postmenopausal woman with no relevant personal medical or surgical record and no first-degree family history of cancer presented with a one-year palpable mass in the right breast, associated over the past five months with sporadic episodes of tachycardia and hot flashes.

On physical examination, a 4 × 4 cm, mobile, non-tender mass was palpated, with no skin or nipple changes. Mammography revealed dense breasts, BI-RADS 2, and breast ultrasound showed a solid hyperechoic lesion in the right breast with irregular margins, measuring 17 × 15 mm, with no axillary lymphadenopathy.

Core needle biopsy revealed invasive breast carcinoma of no special type (NST). Immunohistochemistry showed estrogen receptor positivity of 90%, progesterone receptor positivity of 80%, HER2-negative status, and Ki-67 of 3%. As part of the preoperative workup, a contrast-enhanced breast MRI was requested (Figure 1), revealing a lesion in the right breast measuring 5.6 × 4.2 × 2.8 cm, with no infiltration of the skin or the nipple-areola complex.

Staging computed tomography scans revealed a right adrenal mass measuring 52 × 43 mm, with 30-mm hypodense areas within the lesion. Subsequently, a contrast-enhanced abdominal MRI described

a right adrenal tumor measuring  $5.4 \times 3.8 \times 3.8$  cm, transverse–anteroposterior–craniocaudal diameters (T-AP-CC), with a T1 hyperintense component and progressive T2 hypointensity, which suggested hemorrhagic metastatic disease (Figure 2).

The patient was evaluated by the urologic oncology and endocrinology services, who requested additional diagnostic studies. Tests revealed elevated serum and urinary metanephrines, as well as increased chromogranin A levels. Those findings were consistent with the diagnosis of pheochromocytoma. Cardiovascular evaluation revealed no abnormalities in blood pressure or cardiac rhythm.


Given the potential for cardiovascular complications caused by catecholamine release from pheochromocytoma—such as tachyarrhythmias, hypertensive crises, among others—surgical management was prioritized, and a right adrenalectomy via exploratory laparotomy was performed. A combined surgical approach for both neoplasms was not undertaken due to the patient's personal preference. The surgery was uneventful, and histological confirmation of pheochromocytoma was obtained. Histopathological examination revealed a mitotic index of 2 mitoses per 10 high-power fields, with no evidence of necrosis or capsular or lymphovascular invasion. Immunohistochemistry showed synaptophysin positivity, chromogranin positivity, focal S-100 positivity, and inhibin negativity.

Three months after the first surgery, a modified radical mastectomy was performed. The pathological examination revealed an invasive breast carcinoma of no special type (NST), with macroscopic measurements of 60mm, histological grade II, with presence of lymphovascular invasion, probable perineural invasion, and lymph node involvement (seven lymph nodes involved by neoplasia, three with macrometastases and four with extranodal extension), staged as pT3 pN2 M0 (clinical stage IIIA and clinical prognostic stage IIA).

Adjuvant chemotherapy was initiated with an anthracycline-based regimen. The patient received four cycles of the AC regimen (Doxorubicin  $60 \text{ mg/m}^2$  and Cyclophosphamide  $600 \text{ mg/m}^2$ ) and experienced gastrointestinal toxicity (grade 3 nausea and grade 2 emesis), as well as grade 2 asthenia.


She is currently receiving weekly Paclitaxel at a dose of  $80 \text{ mg/m}^2$ , with good tolerance and no toxicities reported to date (a total of four cycles are planned). Subsequently, hormone therapy with Anastrozole was indicated for a minimum of 5 years, along with radiotherapy to the chest wall and axillary region.

**Figure 1.** Contrast-enhanced breast MRI: In the right breast, upper outer quadrant, anterior and middle thirds (between the 8 and 12 o'clock positions and 2 cm from the nipple) a mass-type lesion with irregular margins is identified. The lesion shows intermediate T2 signal intensity, diffusion restriction, and early contrast enhancement with a heterogeneous pattern and a persistent kinetic curve (type I). Peritumoral edema is noted as adjacent to its posterior aspect. The lesion measures  $5.6 \times 4.2 \times 2.8$  cm (AP  $\times$  T  $\times$  L diameters).



**Source:** Hospital Nacional Cayetano Heredia, Lima, Peru

**Figure 2.** Contrast-enhanced abdominal MRI: A mass arising from the lateral limb and body of the right adrenal gland is identified, measuring approximately 5.4 × 3.8 × 3.8 cm (T × AP × CC diameters). The lesion shows a heterogeneous signal, with a central T1 hyperintense and T2 hypointense component, suggesting a hemorrhagic component. The periphery demonstrates diffusion restriction and contrast enhancement predominantly in the venous phases. No signal drop is observed on out-of-phase T1 gradient-echo sequences, suggesting the absence of intralesional fat content.



**Source:** Hospital Nacional Cayetano Heredia, Lima, Peru.

### 3. Discussion

This is the first case reported in South America of a patient with synchronous neoplasms of breast cancer and pheochromocytoma. This is an atypical event since only a few cases have been reported in Europe and the United States [14,15]. Those patients presented with hormone receptor-positive breast cancer at stages amenable to curative surgical management, like our patient.

Following the radical mastectomy, the patient presented with lymphatic dissemination. A possible contributing factor is the delay in surgical management of this neoplasm, as adrenalectomy had to be prioritized due to the cardiovascular risks associated with pheochromocytoma. Given a 60-mm tumor with lymph node metastasis, the patient is a candidate for adjuvant therapy with cyclin-dependent kinase inhibitors, such as Abemaciclib [16,17] or Ribociclib [18,19], which have demonstrated a reduction in the risk of invasive disease recurrence (33% at 5 years and 25% at 3 years, respectively) when combined with endocrine therapy. Surgical management remains the best curative option for pheochromocytoma [20]. There is no indication for chemotherapy in early-stage disease, and even in advanced stages, no consistent overall survival benefit has been observed, with overall response rates (ORR) below 40% [21,22].

The patient's breast cancer was initially an early-stage disease with estrogen receptor positivity and a low proliferative index, making a metastatic adrenal lesion less likely. In the natural history of ductal breast carcinoma, metastases most frequently occur in the bone (30%–62.5%), lung (11%–34%), liver (7.3%–32%), and central nervous system (2%–16%); however, lobular histology may disseminate to more atypical sites, such as the peritoneum or adrenal gland [23,24]. Nevertheless, a case of ductal breast cancer with solitary adrenal metastasis has been reported [25]. Despite this rare association, pheochromocytoma should always be considered as a diagnostic possibility.

### 4. Conclusion

Synchronous neoplasms pose a significant challenge for the diagnosis and management of oncologic patients. Moreover, they are known to be associated with a poorer prognosis and reduced survival. Understanding metastatic patterns and the natural history of malignancies is essential to consider a broader spectrum of differential diagnoses, as reports of patients with an association of these two neoplasms remain scarce.

The incidental detection of pheochromocytoma through imaging studies performed for staging, together with its biochemical confirmation and timely surgical treatment, highlights the importance of a multidisciplinary evaluation from the outset. Furthermore, additional information is needed regarding the clinical presentation, diagnostic process, and individualized management of these neoplasms to facilitate early identification and optimize therapeutic strategies for patients.

## 5. Patient Perspective

In the first months following her diagnosis, the patient described in this case report experienced depressive symptoms. She received therapy through the oncology psychology service, resulting in improvement in her mood and mental health. According to the patient, the most challenging aspect of her illness has been recovery from consecutive surgeries. She is currently experiencing postoperative complications (abdominal incisional hernia/eventration) secondary to the first surgery.

She experienced multiple toxicities during the initial cycles of chemotherapy; however, she currently reports a sense of well-being and demonstrates good tolerance to systemic treatment.

## 6. Abbreviations

- No Special Type (NST)
- Magnetic Resonance Imaging (MRI)
- Transverse (T)
- Anteroposterior (AP)
- Craniocaudal (CC)
- Longitudinal (L)

## 7. Administrative Information

### 7.1 Supplementary Files

None.

### 7.2 Acknowledgements

The authors would like to thank all healthcare personnel of Hospital Nacional Cayetano Heredia, Lima, Peru, who contributed to the diagnosis and treatment of the patient.

### 7.3 Author Contributions

- Sheila María Huertas Tirado: Conceptualization, writing – original draft, investigation, manuscript review and editing, and final approval of the manuscript.
- José Luis Vargas Mejía: Conceptualization, investigation, reference management.
- Ciro Bryan Espejo Alencastre: Writing – original draft.

### 7.4 Funding

None.

## 7.5 Availability of Data and Materials

Data are available upon reasonable request from the corresponding author. No additional materials are reported.

## 8. Declarations

The authors declare no conflicts of interest. Written and verbal informed consent was obtained from the patient for publication of this case report.

## 9. References

1. De Luca A, Frusone F, Vergine M, Cocchiara R, La Torre G, Ballesio L, et al. Breast Cancer and Multiple Primary Malignant Tumors: Case Report and Review of the Literature. *In Vivo* [Internet]. 2019 [cited 2022 May 22];33(4):1313–24. <https://doi.org/10.21873/invivo.11605>
2. Pan SY, Huang CP, Chen WC. Synchronous/Metachronous Multiple Primary Malignancies: Review of Associated Risk Factors. *Diagnostics*. 2022 Aug 11;12(8):1940. <https://doi.org/10.3390/diagnostics12081940>.
3. Lv M, Zhang X, Shen Y, Wang F, Yang J, Wang B, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. *Medicine*. 2017 Apr;96(17): e6799. <https://doi.org/10.1097/MD.00000000000006799>
4. Pariyada Tanjak, Bhoom Suktitipat, Nutchavadee Vorasan, Panudeth Juengwiwattanakitti, Benjarat Thiengtrong, Cholticha Songjang, et al. Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study. 2021 Sep 23;21(1). <https://doi.org/10.1186/s12885-021-08766-9>
5. Kwon JH, Kim H, Lee JK, Hong YJ, Kang HJ, Jang YJ. Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea. *Cancers*. 2024 Jun 26;16(13):2346–6. <https://doi.org/10.3390/cancers16132346>
6. Singnurkar A, Swaminath A, Metser U, Langer DL, Darling GE, Pond GR. The impact of synchronous malignancies on survival in patients with early stage curable non-small-cell lung cancer. *Cancer Treat Res Commun*. 2020; 25:100246. <https://doi.org/10.1016/j.ctarc.2020.100246>
7. Shin S, Park H, Sung Y, Yoo C, Dae Wook Hwang, Park J, et al. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. *Cancer Research and Treatment* [Internet]. 2018 Oct 15 [cited 2024 Jan 20];50(4):1175–85. <https://doi.org/10.4143/crt.2017.494>
8. Amer M. Multiple neoplasms, single primaries, and patient survival. *Cancer Management and Research*. 2014 Mar;119. <https://doi.org/10.2147/CMAR.S57378>
9. Chen H, Yin S, Xiong Z, Li X, Zhang F, Chen X, et al. Clinicopathologic characteristics and prognosis of synchronous colorectal cancer: a retrospective study. *BMC Gastroenterology*. 2022 Mar 13;22(1). <https://doi.org/10.1186/s12876-022-02153-9>
10. Hao L, Zhang L, Xu C, Jiang M, Zhu G, Guo J. Multiple synchronous primary malignant neoplasms: A case report and literature review. *Oncology Letters* [Internet]. 2023 Aug 17 [cited 2024 Jun 29];26(4):428. <https://doi.org/10.3892/ol.2023.14014>
11. Lu M, Zhang X, Chu Q, Chen Y, Zhang P. Susceptibility Genes Associated with Multiple Primary Cancers. *Cancers*. 2023 Dec 10;15(24):5788–8. <https://doi.org/10.3390/cancers15245788>
12. Sas-Korczyńska B, Mituś JW, Kamzol W, Kołodziej Rzepa M, Jakubowicz J, Wysocki WM. Synchronous malignancies in patients with breast cancer. *Nowotwory Journal of Oncology*. 2018 May 23;67(6):336–41. <https://doi.org/10.5603/NJO.2017.0055>
13. Oprita A, Cotan H, Nitipir C. The Prognostic Implications of Synchronous Cancers in Breast Cancer Patients. *Cureus*. 2024 Sep 1. <https://doi.org/10.7759/cureus.68380>
14. Dahake N, Tushir A, Padmanabhan A. Abstract PO5-20-11: Synchronous Breast Cancer and Pheochromocytoma: A Case Series. *Cancer Research*. 2024 May; 84(9): PO5-320-11. <https://doi.org/10.1158/1538-7445.SABCS23-PO5-20-11>

15. Cruz AS, Sa RP, Torres R, Abreu JP. Individualized Anesthetic Management of a Patient with Pheochromocytoma and Concurrent Breast Cancer: A Case Report. *Cureus* [Internet]. 2024 Jun;16(5): e59751. <https://doi.org/10.7759/cureus.59751>
16. Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *The Lancet Oncology* [Internet]. 2022 Dec 6;0(0). [https://doi.org/10.1016/S1470-2045\(22\)00694-5](https://doi.org/10.1016/S1470-2045(22)00694-5)
17. Rastogi P, O'Shaughnessy J, Martín M, Boyle FM, Cortés J, Rugo HS, et al. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results from a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. *Journal of Clinical Oncology*. 2024 Jan 9. <https://doi.org/10.1200/JCO.23.01994>
18. Slamon D, Oleg Lipatov, Zbigniew Nowecki, McAndrew N, Bozena Kukielka-Budny, Daniil Stroyakovskiy, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. *The New England Journal of Medicine*. 2024 Mar 21;390(12):1080–91. <https://doi.org/10.1056/NEJMoa2305488>.
19. Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial. *Annals of oncology: official journal of the European Society for Medical Oncology* [Internet]. 2024 Spring; 36: 149-57. <https://doi.org/10.1016/j.annonc.2024.10.015>
20. Brewczyński A, Kolasińska-Ćwikła A, Jabłońska B, Wyrwicz L. Pheochromocytomas and Paragangliomas—Current Management. *Cancers*. 2025 Mar 19;17(6):1029. <https://doi.org/10.3390/cancers17061029>
21. Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. *Current Treatment Options in Oncology* [Internet]. 2020;21(11):85. <https://doi.org/10.1007/s11864-020-00787-z>
22. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. *The Journal of clinical endocrinology and metabolism* [Internet]. 2009 Aug;94(8):2850–6. <https://doi.org/10.1210/jc.2008-2697>
23. Batra H, Jason Aboudi Mouabbi, Ding Q, Sahin AA, Maria Gabriela Raso. Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights. *Cancers* [Internet]. 2023 Nov 20;15(22):5491–1. <https://doi.org/10.3390/cancers15225491>
24. Panagiotis K, Zotou M, Antonopoulou V, Geordiadi S, Kyriakou A, et al. A rare case of silent metastatic pheochromocytoma with a breast metastasis. *Endocrine Abstracts*. 2025; 110(121). <https://doi.org/10.1530/endoabs.110.EP121>
25. Liu XJ, Shen P, Wang XF, Sun K, Sun FF. Solitary adrenal metastasis from invasive ductal breast cancer: an uncommon finding. *World journal of surgical oncology* [Internet]. 2010; 8:7. <https://doi.org/10.1186/1477-7819-8-7>